Viking Therapeutics, Inc.
VKTX
$33.31
$0.110.33%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -43.68% | -28.83% | -42.01% | -12.09% | 18.67% |
| Total Depreciation and Amortization | 0.90% | 0.91% | 26.44% | 16.00% | 1.35% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | 0.00% | 33.33% | -35.71% |
| Total Other Non-Cash Items | 35.68% | 399.70% | -57.78% | 135.30% | -67.94% |
| Change in Net Operating Assets | 147.83% | -713.27% | 337.98% | 87.12% | -150.24% |
| Cash from Operations | 10.07% | -67.83% | -41.98% | 22.98% | -364.84% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -32.79% | 860.59% | -74.58% | 120.55% | 72.58% |
| Cash from Investing | -32.79% | 860.59% | -74.58% | 120.55% | 72.58% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 45.27% | -65.10% | -60.35% | -13.18% | -99.55% |
| Repurchase of Common Stock | -- | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 45.27% | -65.10% | -60.35% | -13.18% | -99.52% |
| Foreign Exchange rate Adjustments | -1,300.00% | 101.35% | -155.17% | -1,066.67% | 106.25% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -136.04% | 147.59% | -468.02% | 104.24% | -208.28% |